MAP2K7 and non-small cell lung carcinoma: To date, four MEK inhibitors, trametinib, binimetinib, selumetinib, and cobimetinib, have been approved by the United States Food and Drug Administration, but only trametinib in combination with dabrafenib has been approved for the treatment of NSCLC patients with the BRAF V600E mutation [73].